journal article·2018-10-31Open access

Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages

Alexandre C. C. Vieira, Luíse L. Chaves, Marina Pinheiro, Sofia A. Costa Lima, Domingos Ferreira, Bruno Sarmento, Salette Reis

Abstract

Tuberculosis (TB) is still a devastating disease and more people have died of TB than any other infectious diseases throughout the history. The current therapy consists of a multidrug combination in a long-term treatment, being associated with the appearance of several adverse effects. Thus, solid lipid nanoparticles (SLNs) were developed using mannose as a lectin receptor ligand conjugate for macrophage targeting and to increase the therapeutic index of rifampicin (RIF). The developed SLNs were studied in terms of diameter, polydispersity index, zeta potential, encapsulation efficiency (EE) and loading capacity (LC). Morphology, in vitro drug release and differential scanning calorimetry studies, macrophage uptake studies, cell viability and storage stability studies were also performed. The diameter of the SLNs obtained was within the range of 160-250 nm and drug EE was above 75%. The biocompatibility of M-SLNs was verified and the internalization in macrophages was improved with the mannosylation. The overall results suggested that the developed mannosylated formulations are safe and a promising tool for TB therapy targeted for macrophages.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lipid Membrane Structure and Behavior · Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

UCIBIO, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto

UCIBIO, REQUIMTE, Laboratório de Tecnologia Farmacêutica, Departamento de Ciências do Medicamento, Faculdade de Farmácia, Universidade do Porto

I3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto

INEB – Instituto de Engenharia Biomédica, Universidade do Porto

CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde

Funding

FCT · Ministério da Educação e Ciência · Fundo Europeu de Desenvolvimento Regional · Fundação para a Ciência e a Tecnologia · Ministério da Ciência, Tecnologia e Inovação

References (38)

Show source-provided references
1. 10.3109/21691401.2014.96274510.3109/21691401.2014.962745 ↗
2. WHO. Global tuberculosis report 2016. Switzerland: WHO Library Cataloguing-in-Publication Data; 2016.
3. 10.1128/mBio.00342-1610.1128/mBio.00342-16 ↗
4. 10.1038/mi.2011.1410.1038/mi.2011.14 ↗
5. 10.1016/j.addr.2016.04.01210.1016/j.addr.2016.04.012 ↗
6. Kolyva AS Karakousis PC. Old and new TB drugs: mechanisms of action and resistance understanding tuberculosis – new approaches to fighting against drug resistance. London UK: InTech; 2012.
7. 10.1016/S2213-2600(15)00063-610.1016/S2213-2600(15)00063-6 ↗
8. 10.1038/nrd400110.1038/nrd4001 ↗
9. Arun B, Narendar D, Veerabrahma K. Development of olmesartan medoxomil lipid-based nanoparticles and nansuspension: preparation, characterization and comparative pharmacokinetic evaluation. Artif Cell Nanomed B. 2017;46:126–137.
10. Radtke M, Souto EB, Muller RH. Nanostructured lipid carriers – a novel generation of solid lipid drug carriers. Pharm Technol Eur. 2015;17:45–50.
11. 10.2147/DDDT.S10439510.2147/DDDT.S104395 ↗
12. 10.1517/17425247.5.6.70310.1517/17425247.5.6.703 ↗
13. 10.1016/j.ijpharm.2016.08.00810.1016/j.ijpharm.2016.08.008 ↗
14. 10.1016/j.jconrel.2010.09.00310.1016/j.jconrel.2010.09.003 ↗
15. 10.2147/IJN.S10490810.2147/IJN.S104908 ↗
16. 10.1016/j.carbpol.2012.01.05110.1016/j.carbpol.2012.01.051 ↗
17. 10.1088/1361-6528/28/5/05560310.1088/1361-6528/28/5/055603 ↗
18. 10.1016/j.ijpharm.2014.03.00510.1016/j.ijpharm.2014.03.005 ↗
19. 10.1039/C6RA02020H10.1039/C6RA02020H ↗
20. 10.1039/C5RA19793G10.1039/C5RA19793G ↗
21. 10.2217/nnm.14.11610.2217/nnm.14.116 ↗
22. 10.1016/j.toxlet.2009.04.01710.1016/j.toxlet.2009.04.017 ↗
23. 10.1007/s11095-006-9174-310.1007/s11095-006-9174-3 ↗
24. 10.2147/IJN.S3784010.2147/IJN.S37840 ↗
25. 10.1016/S0169-409X(00)00118-610.1016/S0169-409X(00)00118-6 ↗
26. 10.1016/j.ijpharm.2012.07.05810.1016/j.ijpharm.2012.07.058 ↗
27. 10.1208/pt080408310.1208/pt0804083 ↗
28. 10.1016/j.colsurfb.2014.10.04710.1016/j.colsurfb.2014.10.047 ↗
29. 10.1111/j.1348-0421.1992.tb02035.x10.1111/j.1348-0421.1992.tb02035.x ↗
30. 10.1021/mp500467410.1021/mp5004674 ↗
31. 10.1016/j.jconrel.2012.12.02110.1016/j.jconrel.2012.12.021 ↗
32. 10.1007/s11095-015-1788-x10.1007/s11095-015-1788-x ↗
33. 10.1016/j.jcis.2015.10.05710.1016/j.jcis.2015.10.057 ↗
34. 10.1166/jbn.2013.160010.1166/jbn.2013.1600 ↗
35. 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
36. 10.1021/acs.molpharmaceut.6b0077310.1021/acs.molpharmaceut.6b00773 ↗
37. 10.1074/jbc.271.1.25010.1074/jbc.271.1.250 ↗
38. 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D ↗